| 摘要 |
Compounds of the formula (I) or (II) and their pharmaceutically acceptable salts are ligands at gastrin and/or chole-cystokinin receptors. n is from 1 to 4; R<superscript>4 >is C<subscript>1 </highlight>to C<subscript>15 </highlight>hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; Z is -(NR<superscript>5>)<subscript>a</highlight>-CO-(NR<superscript>6>)<subscript>b</highlight>-(wherein a is 0 or 1, b is 0 or 1, and R<superscript>5 >and R<superscript>6 >are independently selected from H, Me, Et, Pr, Bn), -CO-NR<superscript>5>—CH<subscript>2</highlight>-CO-NR<superscript>6>—, -CO-O-, -CH<subscript>2</highlight>-CH<subscript>2</highlight>-, -CH=CH-, CH<subscript>2</highlight>-NR<superscript>6>— or a bond; Q is R<superscript>7>V, or(a) wherein R<superscript>7 >is -CH<subscript>2</highlight>-; -CH<subscript>2</highlight>-; or(b) R<superscript>7 >and R<superscript>6>, together with the nitrogen atom to which R<superscript>6 >is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is -CO-NH-SO<subscript>2</highlight>-Ph, -SO<subscript>2</highlight>-NH-CO-Ph, CH<subscript>2</highlight>OH, or a group of the formula -R<superscript>8>U, (wherein U is -COOH, tetrazolyl, -CONHOH- or -SO<subscript>3</highlight>H; and R<superscript>8 >is a bond; C<subscript>1 </highlight>to C<subscript>6 </highlight>hydrocarbylene, optionally substituted by hydroxy, amino or acetamino; -O-(C<subscript>1 </highlight>to C<subscript>3 </highlight>alkylene)-; -SO<subscript>2</highlight>NR<superscript>9>—CHR<superscript>10>—; -CO-NR<superscript>9>CHR<superscript>10>—, R<superscript>9 >and R<superscript>10 >being independently selected from H and methyl; or -NH-(CO)<subscript>c</highlight>-CH<subscript>2</highlight>-, c being 0 or 1); m is 1 or 2; q is from 0 to 2, with the proviso that q is 1 or 2 when Z is a bond); Compositions comprising a compound of formula (I) or (II) are also described.
|
